Xenetic Biosciences Inc (XBIO) Stock Analysis

Xenetic Biosciences Inc (XBIO) is a publicly traded company in the HEALTHCARE sector. It trades at $3.38, carries a market capitalization of $7.58M. This page summarizes the public market data, fundamentals, and frequently asked questions for XBIO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Xenetic Biosciences Inc currently has a Bullish sentiment score of 0.38.

About Xenetic Biosciences Inc

Xenetic Biosciences Inc. is a forward-thinking biopharmaceutical company located in Framingham, Massachusetts, specializing in the development of next-generation cancer therapies. Through its proprietary XCART platform, the company is pioneering customized chimeric antigen receptor T (CAR T) cell treatments that specifically target and destroy tumor neoantigens unique to individual patients. Committed to addressing critical unmet medical needs in oncology, Xenetic is poised to significantly e...

GNG Research Analysis

GNG Research scores Xenetic Biosciences Inc (XBIO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for XBIO.

Frequently Asked Questions

Does XBIO pay dividends?

Xenetic Biosciences Inc (XBIO) does not currently pay a regular dividend.

What is XBIO's market cap?

Xenetic Biosciences Inc (XBIO) has a market capitalization of $7.58M with a current stock price of $3.38.